Hi all
We are planning to use DREADD mice (hM4Di) to chronically suppress (2-6 weeks) the proprioceptive system at the level of the spinal cord and peripheral nerves, then look for our phenotype.
I would like advice regarding the ligand administration method and the type of ligand-
As I understand it, most relevant administration methods in the literature include:
1. Daily intraperitoneal injections (once a day, twice a day, more?)
2. Daily subcutaneous injections (once a day, twice a day, more?)
3. Continuous water administration
Regarding the ligand type- I understood CNO has a short half-life in its water soluble form, also it back metabolizes to clozapine, I did not find any relevant publications which used Compound 21 or Perlapine dihydrochloride or publication on any unwanted effects.
Does anyone have thoughts, recommendations or advice on the ligand type and administration methods?
With kind regards,
Eldad
Hello,
We use DREADDs tools in our lab on rats with intra-peritoneal injection and it's the case of most of the paper I see. In mice, Thompson et al 2018, ACS or Jendryka et al 2019 Sci. Rep., use C21 in mice, with both in vitro and in vivo experiment.
For a rapid history of DREADDs ligands, pitfalls and advantage, you can read this general commentary in eNeuro. It also proposed advice and recommandation to avoid bias in behavioral experiment.
https://www.eneuro.org/content/6/5/ENEURO.0171-19.2019
Kind regards,
Raphael
